It was the first dipeptidyl peptidase IV (DPP4) inhibitor for the treatment of T2DM, which mainly reduced the degradation of glucagon-like peptide-1 (GLP-1) by selectively inhibiting the activity of DPP4, thereby exerting hypoglycemic effect (6). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.